FDA Approves New Drug Application for Hepatorenal Syndrome

The Federal Drug Administration (FDA) has approved a California-based company’s Investigational New Drug (“IND”) application for LJPC-501, targeted at patients with hepatorenal syndrome.

As quoted in the market news:

“We are excited to bring a second compound into the clinic this year, especially for a disease such as HRS, in which no approved therapies are available,” said George Tidmarsh, MD, PhD, President and CEO of La Jolla Pharmaceutical Company. (OTCBB:LJPC). “La Jolla is committed to providing therapies for patients with life-threatening diseases, and the approval of our IND for LJPC-501 is an important step in the process toward meeting this goal.”

La Jolla will start a Phase 1 clinical trial of LJPC-501 in patients with hepatorenal syndrome (“HRS”), Type 1 and Type 2.

Click here for the press release by La Jolla Pharmaceutical Company (OTCBB:LJPC)